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Abstract
Background: In West Africa where HIV-1 and HIV-2 co-circulate, the co-infection with hepatitis B virus (HBV) and
hepatitis Delta virus (HDV) is not well described. This study aimed at estimating the prevalence of HBV and HBV/HDV
co-infection according to HIV types and risk factors for HBV infection among West African HIV-infected patients.
Method: A cross-sectional survey was conducted within the IeDEA West Africa cohort from March to December 2012
in Côte d’Ivoire (three sites), Burkina Faso and Mali (one site each). All HIV-infected adult patients on antiretroviral therapy
(ART) or not who attended one of the participating HIV clinics during the study period and agreed to participate were
included. Blood samples were collected and re-tested for HIV type discrimination, HBV and HDV serology as well as HBV
viral load. Logistic regression was used to identify risk factors for HBV infection.
Results: A total of 791 patients were included: 192 HIV-1, 447 HIV-2 and 152 HIV-1&2 dually reactive. At time of sampling,
555 (70.2%) were on ART and median CD4+ cell count was 472/mm3 (inter-quartile range [IQR]: IQR: 294–644). Sixty-seven
(8.5%, 95% CI 6.6–10.6) patients were HBsAg positive without any difference according to HIV type (7.9% in HIV-1, 7.2% in
HIV-1&2 dually reactive and 9.4% in HIV-2; p = 0.61). In multivariate logistic analysis, age ≤ 30 years old (adjusted odds
ratio [aOR] 5.00, 95% CI 1.96–12.76), age between 31 and 49 years old (aOR 1.78, 95% CI 1.00–2.21) and male gender (aOR
2.15, 95% CI 1.25–3.69) were associated with HBsAg positivity. HBV DNA testing was performed in 36 patients with blood
sample available (25 on ART) and 8 (22.2%) had detectable HBV DNA. Among the HBsAg-positive individuals, 14.9% (95%
CI 7.4–25.7) were also positive for anti-HDV antibody without any difference according to HIV type (28.6% in HIV-1, 14.3%
in HIV-2 and 0.0% in HIV-1&2 dually reactive; p = 0.15).
Conclusion: HBV and HBV/HDV co-infection are common in West Africa, irrespective of HIV type. Therefore, screening
for both viruses should be systematically performed to allow a better management of HIV-infected patients. Follow-up
studies are necessary to determine the impact of these two viruses on HIV infection.
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Background
In West Africa, approximately 8% of HIV-infected indi-
viduals have a chronic hepatitis B virus (HBV) infection
[1]. In this part of the world, HBV infection is one of the
main causes of end-stage liver disease, cirrhosis and he-
patocellular carcinoma (HCC) [2].
West Africa is also characterized by the circulation of
both HIV type 1 and 2, which can to lead to co-infections
with HIV-1 and HIV-2 (HIV-1&2) [3–5]. Compared to
HIV-1 infection, HIV-2 infection is characterized by a lon-
ger asymptomatic phase and a slower disease progression
[6]. The management of HIV-2 infection is more challen-
ging than the one of HIV-1, due to the intrinsic resistance
of HIV-2 to non-nucleoside reverse transcriptase inhibi-
tors (NNRTIs) and reduced sensitivity to several protease
inhibitors (PIs) [7, 8].
Due to shared routes of transmission, HIV and HBV
co-infection is common and 5–20% of HIV-infected people
have also chronic HBV infection worldwide [9]. Compared
to HBV or HIV-mono-infected individuals, HIV/HBV-
co-infected patients have a higher risk of impaired
immunological recovery and hepatotoxicity during anti-
retroviral treatment (ART) [10–12] and a faster rate of
progression to cirrhosis and HCC [9]. Thus, knowledge of
HBV status among HIV-infected patients is important for
clinical monitoring and selection of ART, as tenofovir dis-
oproxil fumarate (TDF) and lamivudine (3TC) or emtrici-
tabine (FTC) should be part of the treatment [13].
In West Africa, little is known in about the epidemiology
of hepatitis D virus (HDV) infection, a defective RNA virus
that requires the presence of HBV to infect the hepatocytes
[14]. Its impact on HIV/HBV co-infected patients is not
documented since HDV is not routinely diagnosed. It has
been estimated that approximately 5% of HBV carriers are
co-infected with HDV worldwide [15, 16] and between
3% and 25% in West Africa [17–20]. HDV co-infection
increases the risk for hepatitis flares and chronic hepatic
complications [15, 21] and patients with HBV/HDV co-
infection have a significantly increased risk for HCC
compared with patients with HBV mono-infection and
the general population [22]. Therefore, HDV screening
is very important for the monitoring of HIV/HBV co-
infected patients.
To our knowledge, only one small-scale study from
Guinea Bissau has estimated the prevalence of HDV/HBV
co-infection according to HIV types and did not find any
difference between HIV-1 and HIV-2 [19]. However, this
needs to be confirmed with a large and multicenter study.
The objectives of this study were to estimate the preva-
lence of HBV and HBV/HDV co-infection according to
HIV types among a large series of HIV-infected patients
in the WADA (West Africa Database on Antiretroviral
Therapy) cohort in three West African countries and, to
identify risk factors for HBV seropositivity.
Methods
Study design and settings
A cross-sectional survey was conducted from March to
December 2012 in three countries (Burkina Faso, Côte
d’Ivoire and Mali) within the WADA cohort. This cohort
is embedded in the International epidemiological Database
to Evaluate AIDS (IeDEA) West Africa Collaboration,
which is part of the global IeDEA network [23].
Study population
All patients aged 18 years and above, registered in the
WADA cohort as HIV-2 or dually reactive, who attended
one of the participating clinics during the study period
and who agreed to participate were included in this survey
regardless of ART initiation according to WHO 2010
guidelines [24].
Data collection
A standardized survey form was used to collect data on
patients’ demographics, clinical and biological characteris-
tics. Two EDTA tubes of blood were collected from each
patient and sent to the referral laboratory of the study
(CeDReS, Treichville Hospital in Abidjan, Côte d’Ivoire) to
perform HIV type discrimination and hepatitis analyses.
HIV retesting
All patients identified as HIV-2 or dually reactive on clinical
site according to the national algorithms were screened de
novo with two immuno-enzymatic tests: Immunocomb II
HIV 1 & 2 BISPOT (Orgenics Ltd. Yavne, − Alere), a World
Health Organization (WHO)-endorsed indirect, immuno-
enzymatic test (sensitivity 100%; specificity 99%) [25] and an
in-house ELISA test, developed by the French National Aids
and Viral Hepatitis Research Agency (ANRS) [26]. The
results of this rescreening were previously reported [27].
The aim of this retesting was to perform an accurate HIV
type discrimination, since HIV type misclassification has
previously been reported in many West African cohorts, es-
pecially for HIV-1&2 dually reactive patients [27, 28].
HBV and HDV measurements
Qualitative HBsAg was detected using Monolisa® HBsAg
ULTRA (Bio-Rad, Evolis Tween Plus, Marnes- la- Coquette,
France), a one-step sandwich enzyme immunoassay. Sam-
ples reactive for HBsAg were subsequently tested for HBV
DNA and HDV serology. All tests were performed ac-
cording to manufacturer’s instructions. The quantitative
measurement of HBV DNA in plasma was done with
the COBAS® AmpliPrep/COBAS® TaqMan® HBV Test
(Roche Molecular Systems, Inc. Roche Diagnostics GmbH).
The limit of detection of this assay was 20 IU/ml. Testing
for anti-HDV antibody was performed using ETI-AB-
DELTAK-2, an enzyme immune-assay for the qualitative
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determination of total antibodies to hepatitis delta antigen
(anti-HD) (DiaSorin Limited, United Kingdom).
Statistical analyses
Continuous variables were described with median and
interquartile range (IQR) and categorical variables as
percentages. The prevalence of HBV and HDV infections
was expressed with a 95% confidence interval (95% CI).
Group’s comparisons were performed using Student’s t
test or non-parametric Wilcoxon rank-sum test (non-
normal distribution) for continuous variables and using
Chi-2 test or Fisher’s exact test for categorical variables.
Univariable and multivariable logistic regression analyses
were performed with a stepwise-descending selection
procedure to identify risk factors of HBsAg positivity.
The selection of covariates for multivariable analysis was
based on the univariable analyses with factors associated
with HBsAg positivity (p < 0.25). Adjusted Odds Ratios
(aORs) were reported with 95% CI. We deemed a p-
value <0.05 as statically significant for all analyses. Data
analyses were performed using Stata software (Stata™
11.0 College Station, Texas, USA).
Ethics
This survey was designed and performed in accordance
with the Declaration of Helsinki and was approved by the
national ethics committee of each participating country: the
“Comité d’Ethique pour la Recherche en Santé” (Ministry of
Health and Ministry of Scientific Research and Innovation)
from Burkina-Faso, the “Comité National pour l’Ethique et
la Recherche en Santé” (Ministry of Health and the Fight
against HIV/AIDS) from Côte d’Ivoire and the “Comité
National d’Ethique pour la Santé et les Sciences de la
vie (Ministry of Health)” from Mali. All patients were
informed and had to give their written consent before
being included.
Results
Study population
From March to December 2012, 791 HIV-infected patients
were included in this study: 232 (29.3%) from Burkina Faso,
535 (67.7%) from Côte d’Ivoire and 24 (3.0%) from Mali.
After the retesting for HIV type discrimination, 192 (24.3%)
patients were classified as HIV-1, 447 (56.5%) HIV-2 and
152 (19.2%) as HIV-1&2 dually reactive. At time of sample
collection, the overall median age was 47 years [IQR): 40–
53], 472 (59.7%) were women; median CD4+ cell count was
472 cells/mm3 [IQR: 294–644]; 555 (70.2%) were on ART,
of whom 522 (94.0%) had initiated a regimen composed of
two nucleoside reverse transcriptase inhibitors (NRTIs) and
one PI. Approximately three-quarters of patients (73.2%)
were taking an ART regimen containing 3TC (or FTC)
without TDF and 21.8% an ART regimen containing TDF
and 3TC (or FTC). Median duration on ART was 3.6 years
[IQR: 1.9–6.2]. Table 1 summarizes characteristics of pa-
tients at the time of blood collection.
HBV serology
Sixty-seven patients were tested positive for HBsAg, giving
an overall prevalence of 8.5% (95% CI 6.6–10.6). HBsAg
prevalence did not significantly vary according to country
(9.1% in Burkina Faso, 8.3% in Mali and 8.2% in Côte
d’Ivoire, p = 0.91) or HIV type (7.9% in HIV-1, 7.2% in
HIV-1&2 dually reactive and 9.4% in HIV-2; p = 0.61), but
varied according to gender (11.3% in males vs. 6.6% in
females; p = 0.02) (Table 2).
Among the HBsAg-positive individuals, 51 (76.1%)
were on ART: 48 (94.1%) on a PI-based regimen, two
(3.9%) on a NNRTI-based regimen and one (2.0%) on a
triple NRTI-based regimen. Thirty-one patients (60.8%)
on ART were receiving 3TC (or FTC) without TDF and
17 (33.3%) patients were on TDF + 3TC.
In multivariate analysis adjusting on HIV type, country,
CD4 cell count and ART (Table 2), factors significantly
associated with HBsAg positivity were male gender (aOR
2.15, 95% CI 1.25–3.69), age ≤ 30 years old (aOR 5.00,
95% CI 1.96–12.76) and 31–49 years old (aOR 1.78,
95% CI 1.00–2.21) (Table 2).
HBV viral characteristics
Among 67 HBsAg-positive individuals, 36 (53.7%) had a
blood sample available for HBV DNA measurement and
among them, 25 (69.4%) were on ART including 16 on
3TC and seven on TDF plus 3TC. There were no significant
differences in socio demographic characteristics between
patients with and without HBV DNA measurement, except
for HIV type (85.7% of HBV DNA measurement in HIV-1
infected patients, 40.5% in HIV-2 and 63.6% in HIV-1&2,
p = 0.01). Overall, HBV DNA was detected in eight of 36
patients (22.2%) and the median HBV DNA was 42,050 IU/
ml [IQR: 51–79,100,000]. The proportion of patients with
undetectable HBV DNA was not significantly different
according to ART regimen (100.0% with TDF + 3TC
(or FTC), 87.5% with 3TC and 50.0% with ART without
3TC or TDF; p = 0.25). The detection rate was not sig-
nificantly different according to HIV type (25.0% in
HIV-1, 23.5% in HIV-1&2 dually reactive and 14.3% in
HIV-2; p = 1.00), while it was significantly higher in pa-
tients not on ART compared to those on ART (45.5%
vs 12.0%; p = 0.04).
HDV co-infection
Ten (14.9%, 95% CI 7.4–25.7) of the 67 HBsAg-positive
individuals were tested positive for anti-HDV antibody.
Six of them were on ART, including three on 3TC and
one on TDF + 3TC (FTC). There was no statistical dif-
ference in anti-HDV antibody prevalence according to
type of HIV, although the proportion tended to be high
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among HIV-1 infected patients (28.6% in HIV-1, 14.3%
in HIV-2 and 0.0% in HIV-1&2 dually reactive; p = 0.15).
There was also no statistical difference in this prevalence ac-
cording to all the other characteristics displayed in Table 1.
The prevalence of anti-HDV antibody positivity did not
differ according to HBV DNA detectability (21.4% in
patients with a suppressed HBV DNA vs 25.0% in those
with a detectable HBV DNA; p = 1.00).
Discussion
In this cross-sectional survey, the prevalence of HBV in-
fection and HBV/HDV co-infection were relatively high,
with no statistical difference by country and HIV types.
To our knowledge, this is the largest report up to now on
HBV/HDV co-infection among HIV-infected individuals
in West Africa and the first in the three participating
countries (Burkina Faso, Côte d’Ivoire and Mali). There
are indeed few published studies in this part of the world
[17–19], and none of them, except in Guinea Bissau, has
estimated the prevalence by HIV type [19].
Our study has some limitations. First, about 19% of
the patients were considered as HIV-1 & HIV-2 dually
reactive after the retesting. We were not able to differenci-
ate between HIV-1 or type 2 since we did not perform PCR
DNA for HIV-1 or HIV-2. Second, we did not document
occult HBV infection since HBV DNA was only tested in
HBsAg-positive patients. This has probably underestimated
the prevalence of HBV infection. Indeed, in one study con-
ducted in Côte d’Ivoire, 10% of HBsAg-negative patients
had detectable HBV DNA [29]. Third, the lack of molecular
data concerning the HDV as HDV RNA testing has become
a more compelling tool for recognizing active replication.
Table 1 Characteristics of patients at time of blood collection by HIV status – Burkina Faso, Côte d’Ivoire and Mali – IeDEA West
Africa cohort (2012)
Variables Total HIV-1 HIV-2 HIV-1&2 P-value
N = 791 N = 192 N = 447 N = 152
Age (years)
Median [IQR] 47 [40–53] 45 [37–51] 49 [42–54] 47 [42–52] 0.0004
≤ 30 40 (5.1) 14 (7.3) 25 (5.6) 1 (0.7) <0.001
31–49 438 (55.4) 112 (58.3) 224 (50.1) 102 (67.1)
≥ 50 313 (39.5) 66 (34.4) 198 (44.3) 49 (32.2)
Gender
Male 319 (40.3) 76 (39.9) 192 (43.0) 51 (33.6) 0.12
Female 472 (59.7) 116 (60.4) 255 (57.1) 101 (66.5)
Country
Burkina Faso 232 (29.3) 70 (36.4) 81 (18.1) 81 (53.3) <0.001
Côte d’Ivoire 535 (67.7) 116 (60.4) 350 (78.3) 69 (45.4)
Mali 24 (3.0) 6 (3.1) 16 (3.4) 2 (1.3)
CD4 count (cells/mm3)
Median [IQR] 472 [294–644] 405 [276–599] 488 [311–675] 448 [295–615] 0.0001
≤ 200 115 (14.5) 32 (16.7) 64 (14.3) 19 (12.5) 0.54
> 200 676 (85.5) 160 (83.3) 383 (85.7) 133 (87.5)
Antiretroviral treatment
No 236 (29.8) 20 (10.4) 191 (42.7) 25 (16.5) <0.0001
Yes 555 (70.2) 172 (89.6) 256 (57.3) 127 (83.6)
Antiretroviral regimena
Triple NRTI 26 (4.7) 8 (4.7) 13 (5.1) 5 (3.9) 0.95
NRTI + NNRTI 7 (1.3) 3 (1.7) 3 (1.2) 1 (0.8)
NRTI + PI 522 (94.0) 161 (93.6) 240 (93.7) 121 (95.3)
Antiretroviral drugsa 0.34
3TC alone 406 (73.2) 131 (76.1) 177 (69.2) 98 (77.2)
TDF + 3TC (FTC) 121 (21.8) 34 (19.8) 62 (24.2) 25 (19.7)
Others 28 (5.0) 7 (4.1) 17 (6.6) 4 (3.1)
IQR Interquartile range, NRTI nucleoside reverse transcriptase inhibitor, NNRTI Non-nucleoside reverse transcriptase inhibitor, PI Protease inhibitor
aAmong patients on ART only
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This may have overestimated the prevalence of HDV
co-infection. Fourth, due to low amounts of plasma
available, HBV DNA was not performed in all HBsAg-
positive patients, and resistance and genotypic tests
were not performed. In West Africa region, Genotype E
is the predominant genotype [30]. Finally, our study
population was selected based on the local identification of
HIV-2 and dually reactive patients. The HIV-1 subgroup
may thus not be fully representative of all HIV-1 patients in
care in the same clinics. Despite these limitations, this study
has also two major strengths. First it took place in three dif-
ferent West African countries and second it included a
large sample of HIV-infected patients, giving therefore for
the first time a global view of the distribution of HBV and
HBV/HDV co-infection by HIV type in West Africa.
In our study, the prevalence of HBV was 8.5% (95% CI
6.6–10.6) among HIV-infected patients. This result is
consistent with previous studies conducted in West Africa
that have estimated the prevalence of HBV between 7.9%
and 16.8% [17, 19, 31–33]. The variation of this prevalence
according to studies is possibly due to the HBV vaccination
coverage and the specific distribution of some risk factors
for HBV infection. Indeed we found that male patients and
those <50 years old were more likely to be infected with
HBV, which is consistent with previous reports [20, 34–36].
The high prevalence of HBV in these two groups could be
explained by a greater exposure to HBV through sexual
behavior and body mutilations [20, 34, 35], but also by the
early death of older patients infected with HBV during
childhood. Indeed, in sub-Saharan Africa, 25% of adults
who have been infected during childhood die from cirrhosis
or liver cancer [37]. Other risk factors for HBV infection,
such as WHO stage 3 or 4 and CD4 cell count <200 cells/
mm3, were also found in other studies [36].
Only one-third of the patients co-infected with HIV and
HBV received a standard-of-care ART regimen including
TDF and 3TC (or FTC), two drugs active against both HIV
and HBV. The remaining two-thirds were only exposed to
lamivudine for about four years, a situation which is known
to lead to the development of lamivudine-resistant HBV,
from 43% in year 1 to >80% in year 4 [38–40]. Those
patients with long-standing lamivudine-resistant muta-
tions may experience worsening liver disease. Since
2013, WHO recommends TDF and 3TC (or FTC) as
the preferred NRTI option in first-line ART regimen in
adolescents and adults infected with HIV [13, 41], and this
Table 2 Risk factors for HBsAg seropositivity
Univariate analysis Multivariate analysis
Factor No. of patients with data HBsAg positivity OR 95% CI P aOR 95% CI P
Age (years)
≤ 30 40 8 (20.0) 3.48 1.42–8.48 0.006 5.00 1.96–12.76 0.001
31–49 438 38 (8.7) 1.32 0.76–2.30 0.33 1.78 1.00–2.21 0.05
≥ 50 313 21 (6.7) REF - - REF - -
Gender
Male 319 36 (11.3) 1.81 1.09–2.99 0.02 2.15 1.25–3.69 0.005
Female 472 31 (6.6) REF - - REF - -
HIV-type
HIV-2 447 42 (9.4) 1.59 0.77–3.27 0.21 1.66 0.85–3.26 0.14
HIV-1/2 152 11 (7.2) 1.10 0.44–2.72 0.84 1.11 0.48–2.56 0.81
HIV-1 192 14 (7.3) REF - - REF - -
Country
Burkina Faso 232 21 (9.1) 1.11 0.64–1.91 0.71 1.30 0.72–2.36 0.38
Mali 24 24 (8.3) 1.01 0.23–4.46 0.98 1.01 0.20–4.34 0.93
Côte d’Ivoire 535 44 (8.2) REF - - REF - -
CD4 count (cells/mm3)
≤ 200 115 13 (11.3) 1.47 0.77–2.79 0.24 1.43 0.72–2.84 0.31
> 200 676 54 (8.0) REF - - REF - -
Antiretroviral treatment
Yes 555 51 (9.2) 1.39 0.78–2.49 0.24 1.56 0.83–2.95 0.17
No 236 16 (6.8) REF - - REF - -
OR Odds ratio, CI Confidence Interval, aOR Adjusted Odds ratio
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recommendation is gradually endorsed by countries. This
should allow an optimal management of HIV and HBV
co-infection, including occult hepatitis. Indeed, according
to a recent meta-analysis, up to 90% of patients receiving
such a treatment had a suppressed HBV DNA after three
years [42] and resistance to TDF has not yet been de-
scribed in vivo [43, 44]. However, even with WHO guide-
lines for ART use in HIV-infected individuals, including
two molecules active on both HIV and HBV, the benefits
of HBV screening is still important, including referral for
HBV vaccination in susceptible individuals and a better
management of those already infected with HBV disease.
Regarding HDV infection, previous studies in sub-
Saharan Africa have reported a prevalence of HBV/
HDV co-infection ranging between 0.0% and 44.4%
[17, 18, 20, 45, 46]. More recently, one study con-
ducted in Guinea Bissau found a high prevalence of
HDV/HBV co-infection (25.0%), with no statistical dif-
ference according to HIV type [19]. In our study, the
HBV/HDV prevalence was 14.9%, not different by HIV
type. This large variation of HDV prevalence could be
explained by the different settings and populations,
but also by the tests used for HDV diagnosis. Indeed,
in one cohort of over 200 HIV/HBV co-infected indi-
viduals in rural Tanzania, no confirmed case of active
HDV infection (second serology and nucleic acid amp-
lification) was found among the 11 patients who had a
positive anti-HDV antibody screening test [46]. Thus,
all anti-HDV antibody positive samples should be con-
firmed with an additional antibody test or an HDV RNA
test if possible. The management of this triple infection is
complicated. Indeed, the effect of TDF alone or in associ-
ation with 3TC (or FTC) on HDV replication is controver-
sial according to studies [47, 48]. More research and tools
are needed to improve our knowledge on the distribution
and management of HBV/HDV co-infection among HIV-
infected patients.
Finally, this large and multicenter study showed that
like in Guinea Bissau, there was no statistical difference
of the prevalence of HBV or HBV/HDV according to
HIV types [19]. Thus, the specificity of HIV-2 infection
seems to have no impact on the transmission and the
rate of HBV and HBV/HDV infection.
Conclusions
HBV and HBV/HDV co-infection seem to be common
in West Africa, irrespective of HIV type and the country.
Therefore, the screening of both viruses should be sys-
tematically performed in HIV-infected patients to allow
a better management of HIV. Follow-up studies are
needed to improve our knowledge on HDV infection
and to determine the impact of these two viruses on
the course of HIV infection, especially now with the
universal test and treat policy.
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